We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2015 by University Hospital, Angers.
Recruitment status was:  Not yet recruiting
ClinicalTrials.gov Identifier:
First Posted: March 13, 2015
Last Update Posted: March 13, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University Hospital, Angers
Sildenafil has shown potential effects both on vasodilator mechanisms and as an inhibitor of the NO/GMPc Pain activation. The investigators aim at estimating the benefit of sildenafil in term of morbi-mortality in patients with arterial claudication on a multicenter prospective double blind study.

Condition Intervention Phase
Peripheral Arterial Disease Drug: Sildenafil Drug: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Reduction de la Morbi-mortalité Cardiovasculaire Chez l'artériopathe Claudicant Par le Sildenafil

Resource links provided by NLM:

Further study details as provided by University Hospital, Angers:

Primary Outcome Measures:
  • Morbi-mortality : combined criterion (Cardiovascular fatal and non fatal event Improvement of 1 stage) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Quality of life Questionnaire [ Time Frame: 3, 6 and 9 months ]
  • Safety and secondary effects (Headache, Hypotension) (Proportion of Participants with Adverse Event) [ Time Frame: 3, 6 and 9 months ]
    Proportion of Participants with Adverse Events (sildenafil vs. placebo)

  • Walking capacity (treadmill test) [ Time Frame: 3, 6 and 9 months ]
    treadmill test

  • Proportion of revascularized patients [ Time Frame: 6 and 9 months ]

Estimated Enrollment: 400
Study Start Date: September 2015
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Treated group
Sildenafil, oral, 100mg per day
Drug: Sildenafil
100 mg per day
Other Name: Viagra or revatio
Placebo Comparator: Control group
placebo oral
Drug: Placebo
Placebo with same presentation as the active drug

Detailed Description:

Eligible patients will ask to participate after oral and written information. Evaluation of walking capacity (self reported and treadmill measured), co-morbid condition and quality of life (WELCH, SF-36, Edinburg) will be performed at inclusion, after the first dose and at 3 months of oral treatment through sildenafil 100mg/day or placebo from inclusion to 3 months.

Indication for revascularisation will be evaluated at 3 months according to symptoms and walking capacity according to the Rutherford classification.

Primary endpoint is the proportion of patients showing either a fatal events (cardio-vascular or noncardiovascular) or hospitalisation for non fatal cardiovascular events at 6 and 9 months follow up from inclusion.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ABI<0.90
  • Vascular type claudication
  • stable walking impairment for at least 3 months
  • Optimal cardiovasc treatment (Anti-platelet, HMGCoA-Inh, ACE-Inh or AT2 inh)
  • Age > 30 years

Exclusion Criteria:

  • Refuse to participate
  • Administrative protection
  • Severe renal (clearance < 30 ml/min) or hepatic (Child-Pugh C) failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02387450

Contact: pierre ABRAHAM, MD, PhD +33 241353689 piabraham@chu-angers.fr

Centre hospitalier universitaire
Angers, France, 49933
Sponsors and Collaborators
University Hospital, Angers
Principal Investigator: pierre Abraham, MD, PhD University Hospital in Angers
  More Information

Responsible Party: University Hospital, Angers
ClinicalTrials.gov Identifier: NCT02387450     History of Changes
Other Study ID Numbers: Ongoing recording
First Submitted: March 2, 2015
First Posted: March 13, 2015
Last Update Posted: March 13, 2015
Last Verified: March 2015

Keywords provided by University Hospital, Angers:
Maximal walking distance

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents